# Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer

> **NCT03986294** · PHASE2 · UNKNOWN · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 122 (estimated)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** S1 + Nal-IRI
- **DRUG:** Nal-IRI+Leucovorin+5-FU

## Key facts

- **NCT ID:** NCT03986294
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-01
- **Primary completion:** 2022-01-01
- **Final completion:** 2022-01-01
- **Target enrollment:** 122 (ESTIMATED)
- **Last updated:** 2021-01-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03986294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03986294, "Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03986294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*